• Nebivolol Hydrochloride: Benchmarking β1-Selectivity in Tran

  2026-05-30

  This article explores the mechanistic and strategic dimensions of Nebivolol hydrochloride as a selective β1-adrenoceptor antagonist. Bridging recent advances in drug discovery with translational cardiovascular research needs, we dissect the unique position of Nebivolol hydrochloride in enabling rigorous, pathway-specific studies free from mTOR interference. Integrating new evidence from yeast-based screening platforms and a critical review of the competitive landscape, we provide actionable guidance for researchers focused on cardiovascular pharmacology, hypertension, and heart failure.

• Prevotella copri Depletes IPyA to Promote Breast Cancer Prog

  2026-05-29

  This study identifies Prevotella copri as an oncogenic gut microbe in breast cancer, revealing that its enrichment exhausts host indole-3-pyruvic acid (IPyA) and disrupts anti-cancer signaling via UHRF1 and AMPK pathways. The mechanistic insights clarify a direct microbiome–host metabolite axis influencing tumor growth, with implications for targeted intervention and protein detection workflows.

• Nonivamide (Capsaicin Analog): New Frontiers in TRPV1-Mediat

  2026-05-29

  Explore how Nonivamide, a selective capsaicin analog, is unlocking advanced research in TRPV1-driven cancer cell growth inhibition and inflammation modulation. This article delivers unique experimental strategies and translational insight distinct from existing resources.

• Cathepsin B inhibitor CA-074: Protocols, QC, and Limitations

  2026-05-28

  Cathepsin B inhibitor CA-074 (SKU A1926) enables targeted inhibition of cathepsin B in research applications, supporting studies in cancer metastasis, neurotoxicity, and immune modulation where high selectivity and stability are required. It should not be used when broad-spectrum cysteine protease inhibition or long-term solution stability at room temperature is needed. Researchers benefit from product-specific guidance to maximize selectivity and reproducibility.

• Risedronate Sodium: Innovations in Delivery and Mechanistic

  2026-05-28

  Explore how Risedronate Sodium, a potent FPP synthase inhibitor, is revolutionizing osteoporosis and emphysema research through advanced delivery systems and mechanistic insights. This article uniquely details bioavailability breakthroughs and cross-disciplinary protocols for bone and respiratory studies.

• TG003 Cdc2-like Kinase Inhibitor: Workflows for Splicing Mod

  2026-05-27

  TG003 delivers precise, ATP-competitive inhibition of Clk kinases, enabling unparalleled control of alternative splicing in disease models. Its nanomolar potency and selectivity make it the gold-standard for dissecting platinum resistance and advancing exon-skipping therapy.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera

  2026-05-27

  This article reviews recent advances in the discovery of allosteric PDK4 inhibitors as reported by Lee et al., highlighting the development of compound 8c with potent metabolic, anti-allergic, and anticancer effects. Implications for metabolic disease treatment and cross-talk with dopaminergic signaling research are discussed.

• Dantrolene Sodium Salt: Precision Control of DNA Repair Path

  2026-05-26

  Explore how Dantrolene sodium salt, a potent ryanodine receptor antagonist, uniquely empowers researchers to modulate DNA repair outcomes and calcium signaling with nanomolar precision. This article offers advanced guidance for integrating Dantrolene in genome editing and disease modeling workflows, distilling novel insights from recent high-throughput drug repurposing studies.

• Ridaforolimus (Deforolimus): Applied mTOR Inhibition in Canc

  2026-05-26

  Ridaforolimus (Deforolimus, MK-8669) stands out as a highly potent, selective mTOR inhibitor, delivering reproducible anti-cancer and anti-angiogenic effects in preclinical workflows. This article details best-practice protocols, optimization strategies, and the impact of AI-guided senolytic discovery for researchers deploying Ridaforolimus in complex experimental models.

• Paroxetine Does Not Alter Thiothixene Pharmacokinetics in Hu

  2026-05-25

  This study rigorously assessed whether paroxetine pretreatment affects the clearance of thiothixene, a typical antipsychotic agent, in healthy volunteers. Findings show that short-term paroxetine exposure does not significantly modify thiothixene's pharmacokinetics, clarifying drug-drug interaction concerns relevant to schizophrenia therapy.

• ROS-Responsive Lipid Nanoparticles for Tumor-Selective mRNA

  2026-05-25

  This study presents a combinatorial library of biodegradable lipid nanoparticles engineered to respond to intracellular reactive oxygen species (ROS), enabling selective mRNA delivery and gene expression in tumor cells. The findings highlight a new strategy for targeting mutant RAS-driven cancers by leveraging tumor-specific redox environments, with implications for next-generation mRNA therapeutics.

• Miltefosine for Neutrophil Differentiation: Protocols & Inno

  2026-05-24

  Miltefosine (hexadecyl 2-(trimethylazaniumyl)ethyl phosphate) is redefining workflows in hematology by enabling dual modulation of PI3K/Akt and Ras/MEK/ERK pathways. Explore evidence-backed protocols, troubleshooting tips, and the latest research breakthroughs to maximize reproducibility and translational relevance.

• Apoptotic Extracellular Vesicles Drive Lung Adenocarcinoma S

  2026-05-23

  This study reveals that tumor-derived apoptotic extracellular vesicles (apoEVs) promote metastasis and stemness in lung adenocarcinoma by transferring the enzyme ALDH1A1 and upregulating SOX2 via NF-κB activation. These findings highlight a distinct intercellular communication pathway central to tumor recurrence and suggest new therapeutic targets.

• Low-Molecular Weight Inhibitors of the Alternative Complemen

  2026-05-22

  The referenced review systematically elucidates the discovery, selectivity, and therapeutic promise of low-molecular weight inhibitors targeting the alternative complement pathway, particularly factor B and factor D. Its detailed analysis of activation mechanisms and clinical translation provides a robust foundation for researchers developing or applying these inhibitors in complement-mediated disease models.

• Capsaicin-Induced Autophagy Protects BMSCs Under Oxidative S

  2026-05-22

  This study reveals that capsaicin activates autophagy in bone marrow stromal cells (BMSCs) via TRPV1-mediated calcium influx and suppression of the PI3K/AKT/mTOR pathway, improving cell viability and osteogenic differentiation under oxidative stress. The findings highlight novel mechanistic insights into protecting BMSC function, with implications for osteoporosis therapy and cellular stress research.

14605 records 3/974 page Previous Next 12345 下5页 Last page